期刊文献+

奥沙利铂在治疗晚期胃肠道肿瘤中的应用 被引量:8

下载PDF
导出
摘要 目的观察奥沙利铂联合氟尿嘧啶亚叶酸钙治疗晚期胃肠道肿瘤的疗效、不良反应及探索合适的给药方式。方法将30例胃癌病例、33例结肠癌病例、32例直肠癌病例随机分为氟尿嘧啶亚叶酸钙联合顺铂组(对照组)、氟尿嘧啶亚叶酸钙联合单次大剂量奥沙利铂治疗组(处理组1)及氟尿嘧啶亚叶酸钙联合分次小剂量奥沙利铂治疗组(处理组2)。各组中,化疗药物用法分别为对照组CF100mgm2d1~5,5-Fu350mgm2d1~5,DDP25mgm2d1~3;处理组1CF100mgm2d1~5,5-Fu350mgm2d1~5,L-OHP100mgm2d1;处理组2CF100mgm2d1~5,5-Fu350mgm2d1~5,L-OHP35mgm2d1~4,均21天重复,使用4~6周期后评价疗效及不良反应。结果奥沙利铂联合氟尿嘧啶亚叶酸钙治疗晚期胃癌、结肠癌、直肠癌的有效率分别可达40%±、55%±、50%±。奥沙利铂分次给药较单次给药的疗效相同但毒副作用明显降低。结论奥沙利铂分次给药联合氟尿嘧啶亚叶酸钙是治疗晚期胃肠道肿瘤的毒性小、有效率高的方案。
出处 《实用肿瘤学杂志》 CAS 2005年第4期287-289,共3页 Practical Oncology Journal
  • 相关文献

参考文献8

  • 1金懋林.胃癌化学治疗的发展与运用[J].中国肿瘤临床,2000,27(10):792-798. 被引量:150
  • 2金懋林,陈强,程凤歧,陈伟,陈黎,潘良熹,杨宇飞.奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌的研究[J].中华肿瘤杂志,2003,25(2):172-174. 被引量:404
  • 3姚智东,吴洪斌.奥沙利铂的安全性评价[J].中国新药杂志,2003,12(7):567-569. 被引量:79
  • 4Beliberg H, de Gramont A. Oxaliplatin plus 5 - fluorouracil: clinical experience in patients with advanced colorectal cancer [J]. Semin Oncol,1998;25(2):32.
  • 5程颖,张彩霞,张云五.大肠癌内科治疗的现状[J].实用肿瘤学杂志,2002,16(1):69-72. 被引量:13
  • 6Diaz- Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agentin previously untreated colorectal carcinoma patients: a phase Ⅱ multicentric study [J]. Ann Oncol, 1998;9(1) : 105 - 81.
  • 7Extra JM, Marry M, Brienza S, et al. Pharmacokinetics and safetyprofile of oxaliplatin[J]. Semin Oncol, 1998;25(2) : 13 - 221.
  • 8Levi F, Dogliotti L, Perpiont B, et al. Amuhicenter phase Ⅱ trial of intensified chronotherapy with oxaliplation, 5 - Fu and FA in patients with previously untreated metastatic colorectal cancer [J]. Proc Pun Soc Clin Oncol, 1997; 16:2261.

二级参考文献37

  • 1管忠震,何友兼,刘茂珍,周中梅.大剂量醛氢叶酸合并氟脲嘧啶(HDCF/5Fu)治疗晚期胃肠道癌的探讨[J].癌症,1989,8(6):421-424. 被引量:82
  • 2胡发明.奥沙利铂的不良反应和安全性[J].国外医药合成药·生化药·制剂分册,1999,20(3):184-185.
  • 3De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
  • 4Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
  • 5Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
  • 6De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
  • 7De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
  • 8Richard H, Wilson, Tanya Lehky, et al.Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability[J] .J Clin Oncol,2002,20(7):1767 - 1774.
  • 9Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
  • 10Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.

共引文献607

同被引文献43

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部